-
11.发明授权Method for treating pathologies associated with hypoxia using MIF inhibitors 有权使用MIF抑制剂治疗与缺氧相关的病态的方法公开(公告)号：US08741299B2
公开(公告)日：2014-06-03
申请号：US13528350
申请日：2012-06-20
Applicant: Edmund Miller , Yousef Al-Abed , Yinzhong Zhang , Kai Fan Cheng
Inventor： Edmund Miller , Yousef Al-Abed , Yinzhong Zhang , Kai Fan Cheng
IPC: A61K39/395 , A61K31/42
CPC classification number: A61K31/42 , A61K2039/505 , C07K16/24 , C07K2317/70
Abstract: Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.
Abstract translation: 提供了用MIF抑制剂治疗与缺氧相关的病症的方法。 还提供了用MIF抑制剂治疗患有或具有肺动脉高压风险的受试者的方法。 还提供了用MIF抑制剂治疗具有或与其相关的CNS紊乱或具有风险的受试者的方法。 还提供治疗严重慢性肺部疾病，缺氧诱导的右心室肥大或缺氧诱导的肺血管重塑与MIF抑制剂的方法。 还提供了诊断患有肺动脉高压的受试者的方法。
-
公开(公告)号：US08552040B2
公开(公告)日：2013-10-08
申请号：US13086939
申请日：2011-04-14
Applicant: Yousef Al-Abed
Inventor： Yousef Al-Abed
IPC: A01N43/80 , A61K31/42 , C07D261/02
CPC classification number: A61K31/421 , C07D261/04
Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).
Abstract translation: 公开了用作低分子量化合物的药物组合物的方法，其包含用作MIF抑制剂（巨噬细胞迁移抑制因子）的任选取代的异恶唑啉环体系。 具体地说，该化合物可用于治疗涉及炎症活性或促炎细胞因子应答的各种疾病，例如自身免疫性疾病（包括类风湿性关节炎，胰岛素依赖性糖尿病，多发性硬化，移植物抗宿主病，狼疮综合征），哮喘， 关节炎，ARDS，牛皮癣，白细胞介素-2毒性，增殖性血管疾病和各种形式的败血症和败血性休克，以及其他基本MIF反应特征的病症，包括例如肿瘤生长和新生血管形成（血管生成）。
-
公开(公告)号：US20130123299A1
公开(公告)日：2013-05-16
申请号：US13696326
申请日：2011-05-06
Applicant: Yousef Al-Abed , Betty A. Diamond
Inventor： Yousef Al-Abed , Betty A. Diamond
IPC: C07D401/12
CPC classification number: C07D401/12
Abstract: Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds.
Abstract translation: 提供小分子化合物用于治疗狼疮，以及使用这些化合物治疗狼疮的方法。
-
公开(公告)号：US08362053B2
公开(公告)日：2013-01-29
申请号：US12225571
申请日：2007-03-23
Applicant: Yousef Al-Abed
Inventor： Yousef Al-Abed
IPC: A61K31/42 , C07D261/04
CPC classification number: C07D261/04 , A61K31/42 , A61K31/421 , A61K45/06 , Y02A50/385 , Y02A50/411 , A61K2300/00
Abstract: Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.
Abstract translation: 提供式I（I）的各种化合物。 还提供式II（II）的各种化合物。 还提供了包含上述化合物的药物组合物。 此外，提供了哺乳动物抑制巨噬细胞迁移抑制因子（MIF）活性的方法，以及治疗或预防哺乳动物炎症的方法。 还提供了治疗具有败血症，败血病和/或内毒素性休克的哺乳动物的方法。 还提供了治疗具有自身免疫疾病的哺乳动物的方法以及治疗具有肿瘤的哺乳动物的方法。
-
公开(公告)号：US20120178805A1
公开(公告)日：2012-07-12
申请号：US13418877
申请日：2012-03-13
Applicant: Yousef Al-Abed
Inventor： Yousef Al-Abed
IPC: A61K31/27 , C07C311/49 , C07C271/08 , A61P37/06 , A61K31/166 , A61K31/18 , A61P29/00 , C07C251/86 , A61K31/15
CPC classification number: C07C251/86 , C07C281/02 , C07C311/49
Abstract: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.
Abstract translation: 提供式（I）的各种化合物：还提供包含上述化合物的药物组合物。 此外，提供了哺乳动物抑制巨噬细胞迁移抑制因子（MIF）活性的方法，以及治疗或预防哺乳动物炎症的方法。 还提供了治疗具有败血症，败血病和/或内毒素性休克的哺乳动物的方法。 还提供了治疗具有自身免疫疾病的哺乳动物的方法以及治疗具有肿瘤的哺乳动物的方法。
-
Patent Agency Ranking
公开(公告)号：US07928130B2
公开(公告)日：2011-04-19
申请号：US12360290
申请日：2009-01-27
Applicant: Yousef Al-Abed
Inventor： Yousef Al-Abed
IPC: A01N43/60 , A01N43/08 , A61K31/42 , A61K31/34 , C07D261/02 , C07D413/00
CPC classification number: A61K31/421 , C07D261/04
Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).
Abstract translation: 公开了用作低分子量化合物的药物组合物的方法，其包含用作MIF抑制剂（巨噬细胞迁移抑制因子）的任选取代的异恶唑啉环体系。 具体地说，该化合物可用于治疗涉及炎症活性或促炎细胞因子应答的各种疾病，例如自身免疫性疾病（包括类风湿性关节炎，胰岛素依赖性糖尿病，多发性硬化，移植物抗宿主病，狼疮综合征），哮喘， 关节炎，ARDS，牛皮癣，白细胞介素-2毒性，增殖性血管疾病和各种形式的败血症和败血性休克，以及其他基本MIF反应特征的病症，包括例如肿瘤生长和新生血管形成（血管生成）。
-
17.发明申请Treatment Of Type 1 Diabetes With Inhibitors Of Macrophage Migration Inhibitory Factor 审中-公开治疗1型糖尿病与巨噬细胞迁移抑制因子抑制剂公开(公告)号：US20080305118A1
公开(公告)日：2008-12-11
申请号：US10594641
申请日：2005-03-29
Applicant: Yousef Al-Abed
Inventor： Yousef Al-Abed
IPC: A61K39/395 , A61K38/02 , A61K31/713 , C12Q1/02 , C12Q1/68 , A61P3/10 , A61K31/7052
CPC classification number: C07K16/24 , A61K31/42 , A61K2039/505 , C07K2317/73 , C07K2317/76
Abstract: Methods of treating a mammal having type 1 diabetes or a risk for type 1 diabetes are provided. The methods comprise administering to the mammal a pharmaceutical composition comprising an agent that inhibits MIF in the mammal. Also provided are methods of evaluating whether a compound is useful for preventing or treating type 1 diabetes. The methods comprise determining whether the compound inhibits a macrophage migration inhibitory factor (MIF) in a mammal, then, if the compound inhibits the MIF, determining whether the compound inhibits development of type 1 diabetes.
Abstract translation: 提供了治疗1型糖尿病或1型糖尿病风险的哺乳动物的方法。 所述方法包括向哺乳动物施用包含抑制哺乳动物MIF的药物的药物组合物。 还提供了评估化合物是否可用于预防或治疗1型糖尿病的方法。 所述方法包括确定化合物是否抑制哺乳动物的巨噬细胞迁移抑制因子（MIF），然后如果该化合物抑制MIF，则确定该化合物是否抑制1型糖尿病的发展。
-
公开(公告)号：US20070021465A1
公开(公告)日：2007-01-25
申请号：US10574612
申请日：2004-10-07
Applicant: Yousef Al-Abed , Kevin Tracey
Inventor： Yousef Al-Abed , Kevin Tracey
IPC: A61K31/444 , C07D413/14
CPC classification number: C07D413/14 , C07D413/04
Abstract: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (Ia) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (Ia) or (VIIa). The variables of Formulae (I), (Ia), (VII) and (VIIa) are described herein.
Abstract translation: 式（I）的化合物，包含式（Ia）或（VII）化合物的药物组合物和用炎性细胞因子介导的病症治疗受试者的方法，包括向受试者施用式（Ia）或（VIIa）化合物， 。 本文描述了式（I），（Ia），（VII）和（VIIa）的变量。
-
公开(公告)号：US5811401A
公开(公告)日：1998-09-22
申请号：US757234
申请日：1996-11-27
Applicant: Richard J. Bucala , Yousef Al-Abed
Inventor： Richard J. Bucala , Yousef Al-Abed
CPC classification number: C07K5/06086 , C07K5/06139 , A61K38/00
Abstract: The present invention relates to advaced glycosylation endproducts formed by the reaction of arginine-lysine or lysine-arginine dipeptides, optionally as part of a larger protein or amino-containing-biomolecule, with reducing sugars. These AGEs can be used in various diagnostic and therapeutic methods.
Abstract translation: 本发明涉及通过精氨酸赖氨酸或赖氨酸 - 精氨酸二肽（任选地作为较大蛋白质或含氨基的生物分子的一部分）与还原糖反应形成的引导的糖基化终产物。 这些AGE可用于各种诊断和治疗方法。
-
公开(公告)号：US08741924B2
公开(公告)日：2014-06-03
申请号：US13696326
申请日：2011-05-06
Applicant: Yousef Al-Abed , Betty A. Diamond
Inventor： Yousef Al-Abed , Betty A. Diamond
IPC: A61K31/47 , C07D401/02
CPC classification number: C07D401/12
Abstract: Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds.
Abstract translation: 提供小分子化合物用于治疗狼疮，以及使用这些化合物治疗狼疮的方法。
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.024 seconds)
